Novartis v. Dr. Reddy’s: MAYZENT Siponimod Patent Suit Dismissed in 75 Days
Novartis AG asserted two patents covering siponimod formulations against Dr. Reddy’s generic MAYZENT tablets in New Jersey federal court. The case ended via voluntary dismissal without prejudice in just 75 days, leaving open the possibility of future litigation and no merits ruling on the asserted patents.
Novartis exits MAYZENT patent fight without a merits ruling
Novartis AG filed suit on 15 May 2025 in the District of New Jersey against Dr. Reddy’s Laboratories, asserting US11944602B2 and US8492441B2 in connection with Dr. Reddy’s ANDA for generic siponimod tablets (0.25 mg, 1 mg, and 2 mg) — the active ingredient in Novartis’s branded MAYZENT product, indicated for secondary progressive multiple sclerosis. The case was handled by plaintiff counsel Cynthia Stencel Betz and Mark M. Makhail of McCarter & English LLP.
The action was terminated on 29 July 2025, just 75 days after filing, via voluntary dismissal pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). The dismissal was explicitly without prejudice, meaning Novartis retains the right to refile claims on the same patents. Each party agreed to bear its own attorneys’ fees and costs, which is standard in Rule 41 voluntary dismissals at this early stage and suggests no settlement payment or formal agreement was publicly disclosed.
A 75-day lifespan is unusually brief for a Hatch-Waxman ANDA case in New Jersey, a district well-known for pharmaceutical patent disputes. The rapid exit before any substantive court activity suggests the parties may be negotiating a licensing arrangement, a consent judgment, or that Novartis reassessed its enforcement strategy — though the public record is silent on any such considerations. The without-prejudice designation preserves maximum optionality for Novartis going forward.
Filing to Voluntary dismissal in 75 days
75 days — notably short for a Hatch-Waxman ANDA dispute in the District of New Jersey
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s unilateral early exit right
Federal Rule of Civil Procedure 41(a)(1)(A)(i) permits a plaintiff to dismiss an action without a court order before the defendant serves an answer or a motion for summary judgment. This is the most permissive form of voluntary dismissal — it requires no judicial approval and takes effect upon filing. It does not constitute a ruling on the merits of any claim.
No merits adjudicationWithout prejudice — but what does the silence tell us?
The dismissal is expressly without prejudice, meaning Novartis may refile the same patent claims against Dr. Reddy’s if circumstances change. A dismissal with prejudice would have barred any further action on these patents against this defendant. The public record does not specify whether a side agreement, license, or other arrangement accompanies this dismissal — that distinction is material but unknown from available filings.
Refiling remains possibleInnovator preserves all options, patents unchallenged
By dismissing without prejudice, Novartis retains both asserted patents — US11944602B2 and US8492441B2 — in their current grant status with no invalidity or non-infringement finding. The company avoids the risk of an early adverse ruling and can reassert these patents if Dr. Reddy’s ANDA progress or market entry triggers renewed enforcement concern.
Patents intact and enforceableGeneric challenger faces no injunction but no cleared path
Dr. Reddy’s escapes the immediate litigation burden and avoids a potential 30-month Hatch-Waxman stay, which can be triggered by timely ANDA patent suits. However, the without-prejudice dismissal provides no judicial finding that its generic siponimod product is non-infringing or that the asserted patents are invalid. FDA approval and commercial launch remain contingent on the patent landscape remaining uncontested.
No safe harbour establishedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Pharmaceutical innovator — holder of US11944602B2 and US8492441B2 covering siponimodSearch in Eureka ↗ |
| Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Indian generic pharmaceutical manufacturer seeking ANDA approval for siponimod tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Cynthia Stencel Betz | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Mark M. Makhail | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i), confirming this was a unilateral plaintiff action requiring no court order or defendant consent. The explicit ‘without prejudice’ language is legally significant: it preserves Novartis’s full cause of action on both patents. The cost-sharing clause — each party bearing its own fees — is standard at this pre-answer stage and does not suggest any financial settlement. No merits finding was made on infringement, validity, or claim scope of either asserted patent.
US11944602B2 & US8492441B2 — Siponimod formulations for MS therapy
US11944602B2 (application no. US17/209940) and US8492441B2 (application no. US12/655049) both relate to siponimod, a selective sphingosine-1-phosphate receptor modulator approved under the brand name MAYZENT for the treatment of secondary progressive multiple sclerosis. The patents cover aspects of the formulated tablet product — including dosage strengths of 0.25 mg, 1 mg, and 2 mg — and are listed in the FDA Orange Book, forming the basis for Hatch-Waxman paragraph IV patent certification challenges from generic applicants.
Siponimod represents a significant commercial asset for Novartis in the MS franchise. Generic entry would expose this revenue stream to immediate price erosion. The assertion of both a newer patent (US11944602B2) and an older foundational patent (US8492441B2) in the same action is consistent with a layered Orange Book defense strategy designed to extend the effective exclusivity period. Any competitor developing or having developed a generic siponimod product must carefully evaluate whether its formulation and process design clear both patents.
Should you run an FTO against US11944602B2 and US8492441B2?
Any pharmaceutical company with an active or planned ANDA for generic siponimod tablets — or any R&D team developing siponimod-based formulations for MS indications — should treat both asserted patents as live enforcement risks. The without-prejudice dismissal in this case does not extinguish Novartis’s rights. Formulators, process chemists, and regulatory teams at generic manufacturers should confirm their product and process design does not read on the claims of either patent before advancing FDA filings.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of US11944602B2 and US8492441B2, identify prior art that may bear on validity, and surface any related continuation or divisional applications in Novartis’s siponimod portfolio that could present additional risk. Use Eureka to benchmark your formulation design against the claim language and track Orange Book listing status for both patents in real time.
Run a freedom-to-operate analysis on US11944602B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman siponimod and MS drug patent cases
Cases involving Hatch-Waxman ANDA challenges to MS therapy patents in the District of New Jersey — the primary venue for pharmaceutical patent disputes.
What this case signals for the siponimod and MS drug IP landscape
A rapid voluntary dismissal in a Hatch-Waxman dispute typically signals strategic repositioning — not resolution.
Without-prejudice exits preserve Novartis’s enforcement optionality
Novartis’s decision to dismiss under Rule 41(a)(1) before any answer was filed keeps both asserted patents fully armed for future enforcement. IP teams monitoring the MAYZENT franchise should track any refiling against Dr. Reddy’s or other ANDA filers as a leading indicator of Novartis’s broader siponimod defense posture.
No 30-month stay means accelerated ANDA clock for Dr. Reddy’s
In Hatch-Waxman litigation, a timely-filed patent suit can trigger an automatic 30-month stay of FDA approval. With this suit dismissed, that stay mechanism is not in play here. Dr. Reddy’s ANDA timeline is no longer subject to this litigation, though Novartis may refile if FDA action appears imminent.
Novartis v Dr. — key questions answered
Novartis asserted two patents: US11944602B2 (application US17/209940) and US8492441B2 (application US12/655049), both relating to siponimod tablet formulations marketed as MAYZENT for secondary progressive multiple sclerosis. The case was filed in the District of New Jersey on 15 May 2025.
The dismissal was filed under Federal Rule of Civil Procedure 41(a)(1)(A)(i), which allows a plaintiff to voluntarily dismiss before the defendant serves an answer. The public record does not disclose the commercial or strategic reason for the dismissal. The without-prejudice designation means Novartis retains the right to refile the same patent claims against Dr. Reddy’s.
No. A without-prejudice voluntary dismissal under Rule 41(a)(1) carries no merits finding. Both patents remain granted and enforceable. No court ruled on infringement or validity. Novartis can assert either patent in future proceedings against Dr. Reddy’s or any other ANDA applicant.
Seventy-five days is unusually brief for a Hatch-Waxman ANDA case in the District of New Jersey, where such disputes routinely take years to resolve. The speed suggests the parties may have reached a private commercial arrangement, or that Novartis reassessed its litigation strategy early — though neither inference is confirmed by the public docket.
The case concerns Dr. Reddy’s ANDA for generic siponimod tablets in strengths of 0.25 mg, 1 mg, and 2 mg — the generic equivalent of Novartis’s MAYZENT (siponimod) tablets, approved by the FDA for the treatment of secondary progressive multiple sclerosis.
PatSnap Eureka searches patents and litigation data to answer instantly.